TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
蘇崇維Su, Chung-Wei
- 協同主持人
- 執行臨床試驗年資 7 年 9 個月
-
mp1518@cgmh.org.tw
發表文獻
3筆
1
Su CW, Hou MM, Huang PW, Chou YC, Huang BS, Tseng JH, Hsu CW, Chang TC, Lin SM, Lin CC. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma. Am J Cancer Res. 2022 Apr 15;12(4):1606-1620. PMID: 35530291; PMCID: PMC9077059.
2
Teng W, Lin CC, Su CW, Lin PT, Hsieh YC, Chen WT, Ho MM, Wang CT, Chai PM, Hsieh JC, Lin CY, Lin SM. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Am J Cancer Res. 2022 Apr 15;12(4):1899-1911. PMID: 35530282; PMCID: PMC9077079.
3
Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh JC, Chen WT, Ho MM, Hsieh JC, Wang CT, Chai PM, Lin CC, Lin CY, Lin SM. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med. 2022 Dec 5. doi: 10.1002/cam4.5506. Epub ahead of print. PMID: 36468578
